Insomnia treatment
I'll look up insomnia treatment from the medical library for you.
Searching sources...
Reading File
Now let me search the medical library and recent evidence in parallel.
Finding Sources
Searching PubMed
"insomnia"[MeSH Terms] AND "therapy"[MeSH Terms]
Searching the Web
insomnia treatment guidelines 2025 CBT-I pharmacotherapy
Good - found 4 relevant textbook sections. Let me read the most comprehensive ones in parallel.
Reading File
Reading File
Reading File
I have rich content from multiple sources. Let me also quickly read the drug table from Bradley & Daroff and the Maudsley pediatric section.
Reading File
Reading File
I now have comprehensive content from four authoritative textbooks plus current guideline summaries. Here is a complete, well-organized answer.
Insomnia Treatment
Overview
Insomnia is treated using a two-pronged approach: behavioral/psychological therapies (first-line) and pharmacotherapy (adjunctive or when behavioral approaches are unavailable). All major guidelines - American Academy of Sleep Medicine (AASM), European Sleep Society, and others - place Cognitive Behavioral Therapy for Insomnia (CBT-I) above medications as the preferred initial treatment for chronic insomnia.
1. Non-Pharmacological Treatment (First-Line)
Cognitive Behavioral Therapy for Insomnia (CBT-I)
CBT-I is the gold-standard treatment. It is a multicomponent program typically delivered over 6-10 weekly sessions by a trained clinician. It works by addressing maladaptive thoughts and behaviors that perpetuate insomnia. Components include:
- Stimulus control: Use the bed only for sleep/sex; get out of bed if unable to sleep
- Sleep restriction: Limit time in bed to actual sleep time, then gradually extend
- Sleep hygiene education (see table below)
- Cognitive restructuring: Challenge unrealistic beliefs about sleep and consequences of poor sleep
- Relaxation techniques: Progressive muscle relaxation, diaphragmatic breathing
CBT-I shows excellent short- and long-term effectiveness in both younger and older adults. Unlike medications, its benefits are durable and do not carry risks of dependence or tolerance. - Kaplan & Sadock's Comprehensive Textbook of Psychiatry, p. 12733
Brief Behavioral Therapy for Insomnia (BBT-I): A 4-session abbreviated form that focuses purely on stimulus control and sleep restriction. It can be delivered by nurses in primary care - useful when access to CBT-I specialists is limited. - Kaplan & Sadock's, p. 12734
Sleep Hygiene (Key Rules)
| Recommendation |
|---|
| Restrict naps to 30 min, in late morning or early afternoon |
| Exercise regularly; spend time outside daily |
| Avoid caffeine, tobacco, and alcohol after midday |
| Avoid electronics (especially blue light) 2 hours before bed |
| Keep the bedroom dark and cool |
| Limit liquids in the evening |
| Maintain a fixed wake time every morning, regardless of sleep duration |
| Use the bedroom only for sleeping |
2. Pharmacological Treatment (Adjunctive or Second-Line)
Medications should be used short-term, and ideally alongside CBT-I rather than instead of it. CBT-I + medication is superior to medication alone; however, adding medication to CBT-I does not produce clinically meaningful improvements over CBT-I alone (AASM 2025 guidance). - Bradley & Daroff's Neurology, p. 2437
Approved Hypnotics by Drug Class
Non-Benzodiazepine GABA-A Agonists ("Z-drugs") - Preferred over BZDs
| Drug | Dose (mg) | Half-life | Indication |
|---|---|---|---|
| Zolpidem (Ambien) | 5-10 | 1.5-2.4 h | Sleep onset |
| Zolpidem ER (Ambien CR) | 6.25-12.5 | ~2.8 h | Onset + maintenance |
| Zaleplon (Sonata) | 5-10 | 1 h | Sleep onset |
| Eszopiclone (Lunesta) | 1-3 | 5-7 h | Onset + maintenance |
Benzodiazepines (short-term only; higher risk profile)
| Drug | Dose (mg) | Half-life |
|---|---|---|
| Temazepam (Restoril) | 7.5-30 | 8-20 h |
| Triazolam (Halcion) | 0.125-0.25 | 2-4 h |
| Flurazepam (Dalmane) | 15-30 | 48-120 h (very long - avoid in elderly) |
| Estazolam | 1-2 | 8-24 h |
Orexin Receptor Antagonists (dual orexin receptor antagonists, DORAs)
- Suvorexant (Belsomra): blocks wake-promoting orexin signaling; useful for sleep maintenance
- Lemborexant (Dayvigo): similar mechanism; generally well tolerated
- DORAs are considered first-line pharmacotherapy by several current guidelines; not yet well-studied in combination with CBT-I (most RCT data come from older hypnotics)
Melatonin Receptor Agonist
- Ramelteon (Rozerem): MT1/MT2 agonist; no abuse potential; useful for sleep-onset insomnia; ideal for patients with substance abuse history
Low-dose Sedating Antidepressants
- Doxepin (Silenor) 3-6 mg: FDA-approved for sleep maintenance insomnia; acts via H1 histamine antagonism at low doses
- Trazodone: off-label, widely used; sedating due to H1 and 5-HT2 antagonism
- Mirtazapine: off-label; useful if comorbid depression/anxiety
Melatonin
- Modest effect: reduces sleep-onset latency and slightly increases total sleep time
- Short half-life; best taken 3-4 hours before desired sleep time for circadian rhythm disturbances
- Children/adolescents: First-line pharmacological agent, especially for those with autism, ADHD, or neurodevelopmental disorders. Prolonged-release melatonin (Slenyto) is EMA/MHRA-approved for autism + insomnia in children. - Maudsley Prescribing Guidelines, p. 645
3. What to Avoid
- Diphenhydramine (Benadryl), doxylamine (OTC sleep aids): minimally effective, impair sleep quality, cause next-day grogginess
- Benzodiazepines in older adults: The American Geriatrics Society Beers Criteria (2019) issues strong recommendations against benzodiazepines, Z-drugs, sedating antidepressants, and first-generation antihistamines for sleep in adults ≥65 - risk of falls, cognitive impairment, and confusion. - Kaplan & Sadock's, p. 12734
- Alcohol: widely misused as a sleep aid; fragments sleep architecture and suppresses REM
- Long-term hypnotic use: increases fall risk, tolerance, dependence, and cognitive effects - especially in elderly
4. Special Populations
| Population | Key Considerations |
|---|---|
| Older adults | CBT-I preferred strongly; avoid most sedative-hypnotics (Beers Criteria); DORAs and low-dose doxepin are relatively safer |
| Pregnancy | Hypnotics are generally inadvisable; non-pharmacological approaches preferred |
| Children/adolescents | Behavioral interventions first; melatonin is first-line medication (especially ASD, ADHD) |
| Alcoholism/substance use | Avoid BZDs and Z-drugs; ramelteon is safe |
| Sleep apnea | Avoid hypnotics; treat the apnea first |
| Advanced renal/hepatic/pulmonary disease | Hypnotics require caution or avoidance |
5. Treatment Algorithm (Summary)
- Identify and treat underlying causes (pain, depression, anxiety, OSA, medications, substance use)
- Start CBT-I for all patients with chronic insomnia (6-10 sessions; or BBT-I in primary care)
- Add short-term pharmacotherapy if CBT-I is insufficient or unavailable:
- Sleep-onset insomnia: Z-drugs (zolpidem, zaleplon), ramelteon
- Sleep-maintenance insomnia: Eszopiclone, zolpidem ER, suvorexant, low-dose doxepin
- Combination therapy (CBT-I + medication) can be considered for patients needing rapid symptom relief, per AASM 2025 guidance - though medication adds only modest benefit over CBT-I alone
- Taper and discontinue medication once CBT-I skills are established
Sources:
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry (insomnia treatment, behavioral and pharmacologic approaches)
- Bradley & Daroff's Neurology in Clinical Practice (approved hypnotics table)
- Adams & Victor's Principles of Neurology, 12th ed. (pharmacotherapy overview, orexin antagonists, melatonin)
- Maudsley Prescribing Guidelines in Psychiatry, 15th ed. (pediatric melatonin)
- AASM 2025 new conditional recommendations on combination CBT-I + pharmacotherapy
This is a shared conversation. Sign in to Orris to start your own chat.